Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
395
-
Total 13F shares, excl. options
-
54.4M
-
Shares change
-
+127K
-
Total reported value, excl. options
-
$2.47B
-
Value change
-
-$2.32M
-
Put/Call ratio
-
1.05
-
Number of buys
-
181
-
Number of sells
-
-143
-
Price
-
$45.39
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q3 2023
487 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q3 2023.
CRISPR Therapeutics AG - Common Stock (CRSP) has 395 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.4M shares
of 86M outstanding shares and own 63.25% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (7.16M shares), Capital International Investors (6.09M shares), T. Rowe Price Investment Management, Inc. (3.65M shares), Nikko Asset Management Americas, Inc. (3.47M shares), Sumitomo Mitsui Trust Holdings, Inc. (3.47M shares), BlackRock Inc. (2.71M shares), FMR LLC (2.06M shares), STATE STREET CORP (1.88M shares), NEA Management Company, LLC (1.59M shares), and VANGUARD GROUP INC (1.54M shares).
This table shows the top 395 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.